PLIN5 and metabolic dysfunction-associated steatohepatitis: Although CMA seems to act as a compensatory mechanism for lipophagy inhibition in NASH liver, it is reasonable to hypothesize that the persistent biogenesis of small LDs coated by PLIN2, PLIN3, and PLIN5 may not be counteracted.